Literature DB >> 32634042

A new case of congenital ficolin-3 deficiency with primary immunodeficiency.

Fateme Babaha1,2, Hassan Abolhassani3,4, Zahra Hamidi Esfahani1,2, Reza Yazdani2, Asghar Aghamohammadi2.   

Abstract

OBJECTIVES: Human Ficolin-3 (FCN3) is an oligomeric-structured lectin encoded by the FCN3 gene with a pivotal role in the lectin complement pathway. It has anti-microbial activities against bacterial and viral infections and restrains opportunistic pathogens. Mutation in the FCN3 gene is associated with variable clinical manifestations particularly immunologic (infections and autoimmunity) and neurologic complications.
METHODS: In this study, we report a 5-year-old boy with a biallelic mutation in the FCN3 gene using clinical and immunological and genetic evaluations (whole exome sequencing).
RESULTS: Our case is the first national and the eighth case worldwide with a confirmed frameshift mutation associated with Ficolin-3 deficiency. He manifested refractory seizures since early infancy, meningitis, pyelonephritis and was diagnosed with severe primary immunodeficiency.
CONCLUSION: Our case and literature review indicate Ficolin-3 deficiency should be considered in early-onset, premature neonate with a bacterial infection, neurological manifestation and systemic lupus erythematosus like presentations.

Entities:  

Keywords:  FCN3 gene mutation; Ficolin-3 deficiency; H-ficolin; Hakata antigen; combined Immunodeficiency disease

Year:  2020        PMID: 32634042     DOI: 10.1080/1744666X.2020.1792779

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

1.  Association of ficolin-1 and ficolin-3 gene variation and pulmonary tuberculosis susceptibility in a Chinese population.

Authors:  Ye Li; En-Qing You; Wen-Hong Lin; Xiao-Ning Liu; De-Pei Shen; Xin-Li Zhang; Dong-Chun Ma; Hong-Miao Li
Journal:  J Clin Lab Anal       Date:  2021-02-16       Impact factor: 2.352

2.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.